Hemispherx to charge $300 per week for Ampligen under treatment protocol beginning the week of May 26.
Executive Summary
HEMISPHERx TO CHARGE $300 PER WEEK FOR AMPLIGEN ON COST-RECOVERY BASIS for an open-label trial of the drug in chronic fatigue syndrome patients. The trial will initially treat 20 patients. The first patient has been identified and is set to receive the high-molecular weight double-stranded RNA I.V. drug the week of May 26. The patient was featured in a Philadelphia Inquirer article earlier in May; Philadelphia-based Hemispherx (formerly HEM Pharmaceuticals) previously has proved adept at gaining media coverage of Ampligen, as at a 1991 conference when the firm hired Broadgate Consultants to publicize a presentation of Phase II data.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth